Abstract
The mitotic kinase AURORA-A is essential for cell cycle progression and is considered a priority cancer target. Although the catalytic activity of AURORA-A is essential for its mitotic function, recent reports indicate an additional non-catalytic function, which is difficult to target by conventional small molecules. We therefore developed a series of chemical degraders (PROTACs) by connecting a clinical kinase inhibitor of AURORA-A to E3 ligase-binding molecules (for example, thalidomide). One degrader induced rapid, durable and highly specific degradation of AURORA-A. In addition, we found that the degrader complex was stabilized by cooperative binding between AURORA-A and CEREBLON. Degrader-mediated AURORA-A depletion caused an S-phase defect, which is not the cell cycle effect observed upon kinase inhibition, supporting an important non-catalytic function of AURORA-A during DNA replication. AURORA-A degradation induced rampant apoptosis in cancer cell lines and thus represents a versatile starting point for developing new therapeutics to counter AURORA-A function in cancer. [Figure not available: see fulltext.]
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 1179-1188 |
| Seitenumfang | 10 |
| Fachzeitschrift | Nature Chemical Biology |
| Jahrgang | 16 |
| Ausgabenummer | 11 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 1 Nov. 2020 |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gute Gesundheit und Wohlergehen
Fingerprint
Untersuchen Sie die Forschungsthemen von „PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase“. Zusammen bilden sie einen einzigartigen Fingerprint.Dieses zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver